###begin article-title 0
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
###end article-title 0
###begin p 1
K.S. Peggs and S.A. Quezada contributed equally to this paper.
###end p 1
###begin p 2
###xml 636 639 636 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 1333 1336 1333 1336 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 755 760 <span type="species:ncbi:10090">mouse</span>
###xml 772 777 <span type="species:ncbi:9606">human</span>
###xml 789 794 <span type="species:ncbi:10090">mouse</span>
###xml 954 959 <span type="species:ncbi:10090">mouse</span>
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance immune responses against cancer. Despite their preclinical efficacy and promising clinical activity against late stage metastatic melanoma, the critical cellular targets for their activity remains unclear. In particular, debate has focused on whether the effector T cell (Teff) or regulatory T cell (T reg cell) compartment is the primary target of antibody-mediated blockade. We developed a mouse expressing human instead of mouse CTLA-4, allowing us to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma. The data show that although blockade on effector cells significantly improves tumor protection, unicompartmental blockade on regulatory cells completely fails to enhance antitumor responses. However, concomitant blockade of both compartments leads to a synergistic effect and maximal antitumor activity. We conclude that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti-CTLA-4 antibodies during cancer immunotherapy.
###end p 2
###begin p 3
###xml 417 440 417 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Waterhouse et al., 1995</xref>
###xml 691 714 691 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Mandelbrot et al., 1999</xref>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
The T cell receptor CTL-associated antigen 4 (CTLA-4) is recognized as a critical inhibitory regulator of the early stages of T cell expansion, opposing the actions of CD28-mediated costimulation. Genetic disruption of CTLA-4 expression results in a polyclonal CD4-dominated lymphoproliferative syndrome, which is characterized by T cell infiltration of multiple organs and early lethality within 3-4 wk after birth (Waterhouse et al., 1995). This pathology is dependent on interactions of CD28 with its ligands B7-1 and B7-2, as indicated by the lack of disease in CTLA-4/B7-1/B7-2 triple KO (TKO) mice and the protection afforded by repeated administration of CTLA-4 Ig in CTLA-4 KO mice (Mandelbrot et al., 1999).
###end p 3
###begin p 4
###xml 363 381 363 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Leach et al., 1996</xref>
###xml 383 404 383 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Shrikant et al., 1999</xref>
###xml 406 428 406 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">van Elsas et al., 1999</xref>
###xml 430 450 430 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Quezada et al., 2006</xref>
###xml 609 626 609 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Hodi et al., 2003</xref>
###xml 628 645 628 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Phan et al., 2003</xref>
###xml 647 665 647 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Ribas et al., 2005</xref>
###xml 667 685 667 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Peggs et al., 2008</xref>
###xml 125 130 <span type="species:ncbi:10090">mouse</span>
###xml 135 140 <span type="species:ncbi:9606">human</span>
###xml 487 492 <span type="species:ncbi:9606">human</span>
###xml 498 503 <span type="species:ncbi:9606">human</span>
###xml 748 753 <span type="species:ncbi:9606">human</span>
Based on the recognition of the importance of CTLA-4 in the regulation of immune responses, blocking antibodies against both mouse and human forms have been investigated for their potential to boost immunological responses against cancer. Data from preclinical models support a significant role for CTLA-4 blockade in the induction of durable antitumor immunity (Leach et al., 1996; Shrikant et al., 1999; van Elsas et al., 1999; Quezada et al., 2006). Furthermore, clinical trials with human anti-human CTLA-4 (aHuCTLA-4) mAbs show promising early results in the treatment of late-stage metastatic melanoma (Hodi et al., 2003; Phan et al., 2003; Ribas et al., 2005; Peggs et al., 2008). Despite growing experience of their use in the treatment of human cancers, the precise mechanisms underpinning CTLA-4-mediated control of the immune response and, more specifically, the antitumor activity of anti-CTLA-4 antibodies, remain elusive. Two independent, but not mutually exclusive, hypotheses invoke cell autonomous and non-cell autonomous mechanisms.
###end p 4
###begin p 5
###xml 242 243 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 303 324 303 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Chambers et al., 1998</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">1999</xref>
###xml 332 354 332 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Greenwald et al., 2001</xref>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">2002</xref>
###xml 537 566 537 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">van der Merwe and Davis, 2003</xref>
###xml 645 665 645 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Carreno et al., 2000</xref>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 759 760 759 760 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 765 766 765 766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1279 1282 1279 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1298 1319 1298 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bachmann et al., 1999</xref>
###xml 1416 1417 1416 1417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1421 1422 1421 1422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1482 1483 1482 1483 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1489 1493 1489 1493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1572 1589 1572 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Read et al., 2000</xref>
###xml 1591 1595 1591 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">2006</xref>
###xml 1812 1813 1812 1813 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1833 1836 1833 1836 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1958 1975 1958 1975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Read et al., 2006</xref>
###xml 2236 2253 2236 2253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Wing et al., 2008</xref>
###xml 2364 2367 2364 2367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 888 896 <span type="species:ncbi:405018">cardinal</span>
###xml 1531 1535 <span type="species:ncbi:10090">mice</span>
###xml 1952 1956 <span type="species:ncbi:10090">mice</span>
###xml 2083 2087 <span type="species:ncbi:10090">mice</span>
###xml 2260 2264 <span type="species:ncbi:10090">mice</span>
###xml 2368 2372 <span type="species:ncbi:10090">mice</span>
A cell autonomous mechanism of action for CTLA-4, with CTLA-4 acting when expressed in cis of CD28, is supported by several lines of data. Studies of both in vitro and in vivo systems show higher proliferative capacity of CTLA-4-deficient CD4+ and CD8+ T cells when compared with their WT counterparts (Chambers et al., 1998, 1999; Greenwald et al., 2001, 2002). Several mechanisms have been proposed to explain such cell autonomous inhibition, including CTLA-4 outcompeting CD28 for binding to its ligands B7-1 and B7-2 (for review see van der Merwe and Davis, 2003), as well as direct inhibitory signaling through the CTLA-4 cytoplasmic tail (Carreno et al., 2000). In contrast, it has remained more contentious whether CTLA-4 expressed in trans by CD4+CD25+Foxp3+ regulatory T cells (T reg cells) has a direct role in their suppressive function. Constitutive expression of CTLA-4 is a cardinal feature of T reg cells, although the majority of CTLA-4 is found intracellularly in both T reg and conventional T cells, even after activation. Two major findings have supported a non-cell autonomous inhibitory function of CTLA-4. The first is the dominant protection against lethal lymphoproliferation afforded by WT mixed chimerism in the bone marrow transplant model using CTLA-4-/- and WT donors (Bachmann et al., 1999). The second is the ability of CTLA-4 blockade to abrogate the protective effect mediated by CD4+CD25+ T cells in an adoptive transfer model of colitis (where CD4+CD45RBhigh T cell transfer into immunodeficient mice normally results in severe colitis; Read et al., 2000, 2006). However, interpretation of the impact of anti-CTLA-4 on T reg cells is confounded by the direct effects that CTLA-4 blockade has on non-T reg cells within the same systems, whereas isolation of Foxp3-expressing CD4+ T cells from CTLA-4-/- animals requires immunological manipulations that may have influenced T reg cell development (e.g., the use of TKO mice; Read et al., 2006). Nonetheless, the recent demonstration that T reg cell-specific CTLA-4 deficiency in conditional KO (CKO) mice is associated with a profound reduction in their suppressive capacity has definitively proven a role for CTLA-4 in T reg cell-mediated suppression (Wing et al., 2008). CKO mice developed a lethal autoimmune lymphoproliferative syndrome with a slightly slower tempo than CTLA-4-/- mice, illustrating the essential role that CTLA-4 plays in T reg cell function.
###end p 5
###begin p 6
###xml 229 232 229 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 701 718 701 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Wing et al., 2008</xref>
###xml 1018 1038 1018 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Onizuka et al., 1999</xref>
###xml 1040 1060 1040 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Quezada et al., 2008</xref>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 851 866 <span type="species:ncbi:10090">transgenic mice</span>
These recent findings have direct relevance for the clinical development of anti-CTLA-4 antibodies. They highlight the question of which are the relevant cellular targets for their antitumor activity. To date, effector T cells (Teff) have been thought to be the most relevant target for therapeutic activity, but the data from the CKO experiments suggest otherwise by highlighting the critical role that CTLA-4 plays in T reg cell function. The answer is important for the rational development of combinatorial immunotherapeutic strategies. The lack of functional CTLA-4-expressing T reg cell at tumor engraftment in the CKO studies proved sufficient to prevent sustained tumor growth in 60% of mice (Wing et al., 2008). Both we and others, however, have demonstrated that targeted depletion of T reg cells (either with anti-CD25 mAbs or in Foxp3-DTR transgenic mice) can be effective as a prophylaxis but not as a treatment once tumor engraftment is established, a setting which better reflects their clinical usage (Onizuka et al., 1999; Quezada et al., 2008). In addition, it is possible that quantitative or qualitative differences may exist between CTLA-4 ablation and antibody blockade. Thus, the relative importance of antibody-mediated blockade of CTLA-4 in trans on the regulatory compartment as compared with blockade in cis on the nonregulatory compartment in tumor models and clinical applications remains unclear.
###end p 6
###begin p 7
###xml 456 459 456 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1267 1270 1267 1270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
###xml 952 956 <span type="species:ncbi:10090">mice</span>
In this study, we used mice expressing human instead of mouse CTLA-4 to allow assessment of the influence of uni- and bicompartmental blockade on T reg and non-T reg cell compartments during in vitro assays and in an in vivo tumor model of B16/BL6 melanoma. We show that unicompartmental antibody-mediated blockade of CTLA-4 on T reg cells modestly reduced suppressive capacity during in vitro suppressor assays. This effect was exaggerated by use of CTLA4-/- T reg cells derived from stable bone marrow chimeras, from which T reg cells could be isolated without significant contamination by activated effectors. Intriguingly, unicompartmental antibody-mediated blockade of CTLA-4 on T reg cells combined with a GM-CSF-secreting cellular vaccine (Gvax) had no impact on tumor growth kinetics when given after engraftment. Blockade of the non-T reg cell compartment in combination with Gvax resulted in delayed tumor growth and rejection in 12/30 (40%) mice, whereas blockade of both T reg and non-T reg cell populations resulted in rejection in 22/30 (73%; P = 0.0017). Our data are the first to demonstrate the critical importance of synergy between the independent contributions of CTLA-4 blockade in cis and in trans to antitumor activity, illustrating that both Teff and T reg cells are relevant targets for the therapeutic efficacy of anti-CTLA-4 antibodies.
###end p 7
###begin title 8
RESULTS AND DISCUSSION
###end title 8
###begin title 9
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
A transgenic mouse model for unicompartmental CTLA-4 blockade
###end title 9
###begin p 10
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 530 535 <span type="species:ncbi:10090">mouse</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 623 628 <span type="species:ncbi:9606">human</span>
###xml 658 663 <span type="species:ncbi:10090">mouse</span>
###xml 725 730 <span type="species:ncbi:10090">mouse</span>
Much of the difficulty complicating the interpretation of previous studies attempting to define the cellular target of CTLA-4 antibody in blocking experiments has been the presence of CTLA-4 on both activated effector and regulatory compartments. Thus, blockade has potentially affected both populations and assigning relative contributions to experimental endpoints has been impossible. To allow evaluation of unicompartmental CTLA-4 blockade, we have taken advantage of the fact that human CTLA-4 is capable of interacting with mouse B7-1 and B7-2 and generated mice expressing a chimeric CTLA-4 molecule composed of the human extracellular domain and the mouse transmembrane and cytoplasmic domains instead of full length mouse CTLA-4.
###end p 10
###begin p 11
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTLA-4</italic>
###xml 679 682 679 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1125 1133 1125 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 a</xref>
###xml 1214 1215 1214 1215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1220 1221 1220 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1229 1230 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1235 1236 1235 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1250 1258 1250 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 b</xref>
###xml 1306 1314 1306 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 a</xref>
###xml 5 10 <span type="species:ncbi:9606">human</span>
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
###xml 513 518 <span type="species:ncbi:10090">mouse</span>
###xml 552 557 <span type="species:ncbi:9606">human</span>
###xml 599 604 <span type="species:ncbi:9606">human</span>
###xml 630 635 <span type="species:ncbi:10090">mouse</span>
###xml 708 713 <span type="species:ncbi:10090">mouse</span>
###xml 1043 1048 <span type="species:ncbi:10090">mouse</span>
###xml 1095 1100 <span type="species:ncbi:10090">mouse</span>
###xml 1190 1195 <span type="species:ncbi:9606">human</span>
###xml 1281 1286 <span type="species:ncbi:10090">mouse</span>
###xml 1300 1304 <span type="species:ncbi:10090">mice</span>
Both human and mouse CTLA-4 genes are composed of four exons, with overall sequence homology of corresponding proteins of 76% (67% in the extracellular [exon 2], 83% in the transmembrane [exon 3], and 100% in the intracytoplasmic [exon 4] domains). The gene product of exon 1 is a signal peptide not expressed in the mature protein. We created a chimeric 17-kb DNA construct containing putative upstream regulatory sequences required for CTLA-4 expression and in which the extracellular (exon 2) coding domain of mouse CTLA-4 was replaced with that of human CTLA-4. This allowed the generation of a human CTLA-4 transgenic (HuTg) mouse, which was then backcrossed into the CTLA-4-/- background (). This HuTg mouse permitted reconstitution of both in vitro and in vivo experimental systems in which the composition of T reg and non-T reg cell compartments (WT vs. HuTg) could be controlled. The species-specific binding of anti-CTLA-4 antibodies then allowed evaluation of unicompartmental CTLA-4 blockade. Intracellular staining for Foxp3 and mouse CTLA-4 confirmed the absence of expression of mouse CTLA-4 in HuTg T cells (Fig. 1 a). Anti-HuCTLA-4 revealed similar expression profiles of human CTLA-4 in HuTg CD4+Foxp3- and CD4+Foxp3+ populations (Fig. 1 b), as demonstrated for mouse CTLA-4 in WT mice (Fig. 1 a).
###end p 11
###begin p 12
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Functional replacement of mouse CTLA-4 with the human CTLA-4 gene in vivo.</bold>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 293 294 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 394 395 394 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 450 451 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 462 463 462 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 478 479 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 662 666 <span type="species:ncbi:10090">mice</span>
Functional replacement of mouse CTLA-4 with the human CTLA-4 gene in vivo. (a and b) Flow cytometric analysis of intracellular Foxp3 and CTLA-4 in freshly isolated LN CD4+ T cells from WT and HuTg mice, labeled with aMUCTLA-4 (a) and aHuCTLA-4 (b). (c) Absolute CD4+Foxp3+, CD4+Foxp3-, and CD8+ T cell counts from age-matched WT (empty circles) and HuTg mice (filled circles; 8-10-mo-old mice; n = 8-9 per group). (d) Frequency of Ki67-expressing CD4+Foxp3+, CD4+Foxp3-, and CD8+ T cells in LN of WT (empty circles) and HuTg mice (filled circles). (e) Absolute cell counts for B cell, NK cell, and dendritic cell populations in LN of WT (empty circles) and HuTg mice (filled circles). Data represent three independent experiments. Horizontal bars in c-e represent mean values.
###end p 12
###begin p 13
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 416 433 416 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Lute et al., 2005</xref>
###xml 573 581 573 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 c</xref>
###xml 673 674 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 679 680 679 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 792 793 792 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 806 814 806 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 d</xref>
###xml 857 858 857 858 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 863 864 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1190 1198 1190 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 e</xref>
###xml 1653 1671 1641 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Chen, et al., 2000</xref>
###xml 1964 1967 1952 1955 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 328 333 <span type="species:ncbi:10090">mouse</span>
###xml 349 354 <span type="species:ncbi:10090">mouse</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
###xml 714 718 <span type="species:ncbi:10090">mice</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
###xml 1177 1181 <span type="species:ncbi:10090">mice</span>
###xml 1446 1450 <span type="species:ncbi:10090">mice</span>
###xml 1541 1545 <span type="species:ncbi:10090">mice</span>
###xml 1593 1597 <span type="species:ncbi:10090">mice</span>
###xml 1708 1712 <span type="species:ncbi:10090">mice</span>
###xml 1818 1822 <span type="species:ncbi:10090">mice</span>
###xml 1841 1846 <span type="species:ncbi:9606">human</span>
###xml 1885 1890 <span type="species:ncbi:10090">mouse</span>
###xml 1968 1972 <span type="species:ncbi:10090">mice</span>
Homozygous HuTg mice were rescued from the lymphoproliferative phenotype of CTLA-4-/- mice, suggesting normal complementation of CTLA-4 expression in this model. These mice had a normal lifespan with no evidence of autoimmune disease over a period of followup of >12 mo. Similarly to a previously published human CTLA-4 knockin mouse (in which both mouse exon 2 and exon 3 were replaced with their human homologues [Lute et al., 2005]), there was no enlargement of lymphoid organs and no significant increase in absolute numbers of total T cells harvested from either LNs (Fig. 1 c) or spleens (not depicted). There was a small but significant increase in the number of CD4+Foxp3+ T cells in HuTg compared with WT mice, which could be explained by the increased levels of Ki67 in the HuTg CD4+ population (Fig. 1 d). This small increase in the number of CD4+Foxp3+ T cells had no impact on the overall phenotype of other T cells because the extent of activation in vivo in HuTg mice, as assessed by flow cytometry for surface CD44 and CD62L expression, was essentially indistinguishable from that in WT T cells (unpublished data). There were no differences between HuTg and WT mice in LNs (Fig. 1 e) or spleens (not depicted) in terms of numbers of B, dendritic, or NK cells. Furthermore, there was no evidence of increased levels of autoantibodies with age as assessed by antinuclear antibody (ANA) production. ELISAs showed that only 1/11 aged mice (11-12 mo old) had positive titers for ANA, compared with 0/8 in a control group of WT B6 mice (unpublished data). The incidence of ANA in B6 mice has been reported at approximately20% by 10 mo of age (Chen, et al., 2000), suggesting that the rates in HuTg mice are no higher. These data suggest a normal development of the myeloid and lymphoid compartments in these mice and indicate that human CTLA-4 can functionally interact with mouse B7 molecules to prevent the lymphoproliferative disease evident in CTLA-4-/- mice.
###end p 13
###begin p 14
###xml 360 361 360 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 366 367 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 381 382 381 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 387 388 387 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 811 812 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 523 527 <span type="species:ncbi:10090">mice</span>
###xml 937 941 <span type="species:ncbi:10090">mice</span>
###xml 963 968 <span type="species:ncbi:10090">mouse</span>
###xml 1105 1109 <span type="species:ncbi:10090">mice</span>
To further evaluate the regulation of CTLA-4 in HuTg mice, we performed in vitro analyses of CTLA-4 expression, comparing the temporal profiles of up-regulation in WT and HuTg mice after stimulation with anti-CD3 (). The expression patterns of both cell surface and intracellular CTLA-4 were very similar over 72 h when comparing WT and HuTg mice in either CD8+, CD4+FoxP3+, or CD4+FoxP3- compartments, suggesting comparable regulation in the WT and HuTg mice. Finally, we performed tumor challenge experiments in the HuTg mice with either the MC38 colonic carcinoma cell line or the B16 melanoma cell line (both syngeneic), treating with anti-CTLA-4 monotherapy (100 microg aHuCTLA-4, clone 147, on days 3, 6, and 9) or combined anti-CTLA-4 and an irradiated GM-CSF-secreting B16/BL6 cellular vaccine (Gvax; 106 cells on days 3, 6, and 9), respectively. Tumors were rejected with a similar kinetic to that previously demonstrated in WT mice treated with an anti-mouse CTLA-4 (aMuCTLA-4) mAb, suggesting that HuCTLA-4 plays a comparable role in vivo in these tumor model systems to that of MuCTLA-4 in WT mice (unpublished data).
###end p 14
###begin title 15
Unicompartmental CTLA-4 blockade during in vitro suppressor assays results in a modest decrease in suppressive activity
###end title 15
###begin p 16
###xml 68 83 68 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, a and b</xref>
###xml 164 179 164 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, a and b</xref>
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 221 222 221 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 229 230 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 375 383 375 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 506 514 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 b</xref>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
In accordance with the species-specific binding of anti-CTLA-4 mAb (Fig. 1, a and b), functional blockade with an aMuCTLA-4 (clone 9H10) was also species specific (Fig. 2, a and b). Purified populations of either CD4+CD25- or CD4+CD25+ WT T cells proliferated to a significantly greater degree in the presence of aMuCTLA-4 than control IgG in thymidine incorporation assays (Fig. 2 a), whereas neither population of purified cells from HuTg mice showed enhanced proliferation in the presence of aMuCTLA-4 (Fig. 2 b). The direct effect on purified effector and regulatory WT cells highlights the cell autonomous role of CTLA-4 in inhibiting T cell proliferation. The demonstration that aMuCTLA-4 produces functional blockade in a species-specific manner allowed us to examine the effects of unicompartmental blockade of either the T reg or non-T reg cell populations.
###end p 16
###begin p 17
###xml 0 150 0 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Unicompartmental blockade with aMuCTLA-4 during in vitro suppressor assays suggests both cell autonomous and non&#8211;cell autonomous activities of CTLA-4.</bold>
###xml 278 279 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 292 293 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 517 518 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 647 648 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 652 653 652 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 706 707 706 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 711 712 711 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 813 814 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 818 819 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 877 878 877 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 880 883 880 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 891 892 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 896 897 896 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Unicompartmental blockade with aMuCTLA-4 during in vitro suppressor assays suggests both cell autonomous and non-cell autonomous activities of CTLA-4. Suppressor assays were performed using mixtures of WT and HuTg cells. (a and b) Proliferation of 50,000 purified WT or HuTg CD4+CD25- and CD4+CD25+ T cells in response to T cell-depleted splenocytes and anti-CD3 and in the presence of control IgG or aMuCTLA-4, confirming the species specificity of the CTLA-4 blockade. (c) Unicompartmental blockade of 50,000 WT CD4+CD25- T cells with aMuCTLA-4, compared with control IgG during in vitro suppression by addition of increasing numbers of HuTg CD4+CD25+ T reg cells. (d) Unicompartmental blockade of WT CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppression of 50,000 HuTg CD4+CD25- T cells. (e) Bicompartmental blockade of both WT CD4+CD25- Teff and CD4+CD25+ T reg cells with aMuCTLA-4, compared with control IgG during in vitro suppressor assays. Data in a-e represent three or more independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.
###end p 17
###begin p 18
###xml 103 114 103 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, c&#8211;e</xref>
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 350 358 350 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 c</xref>
###xml 451 452 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 467 475 467 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 d</xref>
###xml 677 685 677 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 d</xref>
###xml 999 1000 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1004 1005 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1082 1083 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1087 1088 1087 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1096 1097 1096 1097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1101 1102 1101 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1381 1389 1381 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 e</xref>
Conventional suppressor assays were performed using mixtures of cells purified from WT and HuTg cells (Fig. 2, c-e). Blockade on WT CD4+CD25- T cells in the presence of HuTg T reg cells resulted in increased baseline proliferation, but titration of HuTg T reg cells resulted in equivalent suppression to that seen without aMuCTLA-4 at ratios of 1:1 (Fig. 2 c). By comparison, blockade on WT T reg cells did not increase baseline proliferation HuTg CD4+CD25- T cells (Fig. 2 d). Titration of increasing numbers of WT T reg cells largely suppressed proliferation but reproducibly failed to induce equivalent suppression of thymidine incorporation to that seen without aMuCTLA-4 (Fig. 2 d). These results could be explained by a slight reduction in the suppressive capacity of WT T reg cells after CTLA-4 blockade but do not exclude the possibility that the excess thymidine incorporation occurred within the WT T reg cell compartment in the presence of CTLA-4 blockade and that full suppression of CD4+CD25- T cells was achieved. Bicompartmental blockade in experiments where both CD4+CD25- and CD4+CD25+ T cells were WT showed a possible additive effect of blockade. The baseline proliferation of the non-T reg cell compartment was increased and titration of WT T reg cells resulted in a lesser degree of suppression, which failed to approach complete suppression at ratios of 1:1 (Fig. 2 e). These data suggest that antibody-mediated CTLA-4 blockade influences T cell proliferation by both cell autonomous and non-cell autonomous mechanisms, but with a more subtle effect on T reg cells.
###end p 18
###begin p 19
Different antibodies may display subtle or more obvious differences in terms of mode of action or magnitude of effect. To confirm that these findings were specific neither to one antibody clone nor to blockade of WT CTLA-4, we performed parallel experiments using alternate anti-CTLA-4 antibodies. Results were comparable using the 9D9 aMu-CTLA-4 clone (not depicted) and the aHuCTLA-4 clone 147 (). Thus, the different antibodies seem largely equivalent in terms of in vitro suppressor assays.
###end p 19
###begin title 20
Inhibitory effects of CTLA-4 during in vitro suppressor assays are exaggerated in CTLA-4 KO T cells
###end title 20
###begin p 21
###xml 210 237 210 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">Vijayakrishnan et al., 2004</xref>
###xml 633 636 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 690 693 690 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 1172 1194 1172 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Fallarino et al., 2003</xref>
###xml 1196 1214 1196 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Bodor et al., 2007</xref>
###xml 1468 1486 1468 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Butte et al., 2007</xref>
###xml 1631 1632 1631 1632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1638 1641 1638 1641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1652 1653 1652 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1801 1822 1801 1822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bachmann et al., 1999</xref>
###xml 1824 1828 1824 1828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">2001</xref>
###xml 1849 1852 1849 1852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2122 2123 2122 2123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2128 2129 2128 2129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2181 2184 2181 2184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2240 2241 2240 2241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2254 2255 2254 2255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2273 2274 2273 2274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
###xml 1949 1953 <span type="species:ncbi:10090">Mice</span>
We reasoned that the apparently modest impact of blockade of CTLA-4 on the T reg cell compartment might reflect incomplete functional blockade, the presence and function of a ligand-independent form of CTLA-4 (Vijayakrishnan et al., 2004), or, alternatively, might indicate that suppression in this assay is dependent on alternate pathways. These explanations are not mutually exclusive. If the former were true genetic ablation of CTLA-4 might be associated with heightened effects, whereas this might not occur if alternate pathways were responsible for suppression. The selection of T reg cells based on CD25 expression from CTLA4-/- mice without significant contamination by activated Teff has proven difficult. Generation of CTLA-4/B7-1/B7-2 TKO mice allows isolation of T reg cells from a nonactivated background, but interpretation of subsequent experiments is potentially complicated both by the lack of B7 molecules on antigen-presenting cells during T cell development and on T cells themselves. The impact of the latter is particularly hard to predict. B7 molecules have been demonstrated to mediate reverse signaling into the cell on which they are expressed (Fallarino et al., 2003; Bodor et al., 2007). Furthermore, PD-L1 has recently been revealed to be a specific binding partner of B7-1 with an affinity intermediate between that for CTLA-4 and B7-1 and CD28 and B7-1, with evidence that PD-L1 and B7-1 can mediate bidirectional inhibitory signaling (Butte et al., 2007). We therefore sought to isolate CTLA-4-deficient T reg cells from an alternate source. Because mixed bone marrow chimeras generated from CD45.2+CTLA-4-/- and CD45.1+ WT donors have been shown to be protected from lymphoproliferation and capable of apparently normal responses to challenge with several pathogens (Bachmann et al., 1999, 2001), we purified CTLA-4-/- T reg cells from stable chimeras using the CD45.1 congenic marker to deplete WT (SJL) cells (). Mice were bled 10-12 wk after transplantation and only those displaying 40-60% SJL chimerism were used for subsequent experiments. The profile of CD25 staining on the CD45.1-Foxp3- T cells revealed no excess activation of the CTLA-4-/- non-T reg cells. Purified populations were <0.5% CD45.1+, 96-99% CD25+, and 86-92% Foxp3+.
###end p 21
###begin p 22
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 137 145 137 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 a</xref>
###xml 215 223 215 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 a</xref>
###xml 417 420 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 424 425 424 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 476 477 476 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 481 482 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 509 517 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 b</xref>
###xml 539 542 539 542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 613 614 613 614 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 618 619 618 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 629 637 629 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 c</xref>
###xml 748 751 748 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 913 916 913 916 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 920 921 920 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 925 926 925 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 936 944 936 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 a</xref>
###xml 1001 1004 1001 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1101 1109 1101 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 a</xref>
###xml 1162 1165 1162 1165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1189 1192 1189 1192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1196 1197 1196 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1201 1202 1201 1202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1233 1236 1233 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1240 1241 1240 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1245 1246 1245 1246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1264 1267 1264 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1370 1378 1370 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 d</xref>
###xml 1693 1710 1693 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Wing et al., 2008</xref>
CD4+CD25- and CD4+CD25+CTLA-4-/- T cells both showed enhanced proliferation in thymidine incorporation assays compared with WT controls (Fig. 3 a). The fold increase was greater than that seen with CTLA-4 blockade (Fig. 2 a), which is consistent with a greater impact of CTLA-4 ablation compared with antibody-mediated blockade. Despite higher baseline proliferation, WT T reg cells suppressed proliferation of CTLA-4-/- CD4+CD25- T cells to the same level as seen with WT CD4+CD25- T cells at ratios of 1:1 (Fig. 3 b). In contrast, CTLA-4-/- T reg cells were severely impaired in their ability to suppress WT CD4+CD25- T cells (Fig. 3 c). In this case, the difference was unlikely to be explained solely by an excess of proliferation in the CTLA-4-/- T reg cell compartment, as the differences in absolute counts (cpm) in the proliferation assays were well in excess of those demonstrated for the purified CTLA-4-/- CD4+CD25+ T cells (Fig. 3 a). Furthermore, the flow cytometry profiles of the CTLA-4-/- T cells (Fig. S4) and relatively modest increase in absolute levels of thymidine incorporation (Fig. 3 a) argue against a significant contamination of CTLA-4-/- T reg cells with CTLA-4-/- CD4+CD25- T cells. Suppression of CTLA-4-/- CD4+CD25- T cells by CTLA-4-/- T reg cells was virtually nonexistent in contrast to the full suppression mediated by WT T reg cells (Fig. 3 d). These data confirm that CTLA-4 has a role in both cell autonomous and non-cell autonomous (i.e., T reg cell-mediated) inhibitory regulation of non-T reg cells and also a cell autonomous role within the T reg cell compartment. These data are entirely consistent with those using CKO CTLA-4-deficient T reg cells (Wing et al., 2008).
###end p 22
###begin p 23
###xml 6 9 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 0 94 0 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTLA-4<sup>&#8722;/&#8722;</sup> T reg cell display diminished regulatory activity during in vitro suppressor assays.</bold>
###xml 159 162 159 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 211 212 211 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 225 226 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 230 231 230 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 382 385 382 385 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 441 444 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 448 449 448 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 453 454 453 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 456 459 456 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 497 498 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 502 503 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 549 550 549 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 554 555 554 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 557 560 557 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 604 607 604 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 663 666 663 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 670 671 670 671 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 675 676 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 700 703 700 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 707 708 707 708 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CTLA-4-/- T reg cell display diminished regulatory activity during in vitro suppressor assays. Suppressor assays were performed using mixtures of WT and CTLA-4-/- cells. (a) Proliferation of WT and CTLA-4-/- CD4+CD25- and CD4+CD25+ T cells in response to T cell-depleted splenocytes and anti-CD3, demonstrating cell autonomous inhibitory function of CTLA-4 in the proliferation of Teff and T reg cells. (b) Suppression of 50,000 WT or CTLA-4-/- CD4+CD25- Teff cells by increasing numbers of WT CD4+CD25+ T reg cells. (c) Suppression of 50,000 WT CD4+CD25- Teff cells by increasing numbers of WT or CTLA-4-/- CD4+CD25+ T reg cells. (d) Suppression of 50,000 CTLA-4-/- CD4+CD25- T cells by WT or CTLA-4-/- CD4+CD25+ T reg cells. Data in a-d represent three independent experiments, and in each group replicates were performed as quintuplets. Error bars indicate SD.
###end p 23
###begin title 24
###xml 25 28 25 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
CTLA-4 blockade on both Teff and T reg cell compartments is required for maximal antitumor activity
###end title 24
###begin p 25
###xml 243 251 243 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 d</xref>
###xml 450 470 450 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Quezada et al., 2008</xref>
###xml 800 803 800 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 939 940 939 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 944 945 944 945 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 986 987 986 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 991 992 991 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1000 1001 1000 1001 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1040 1043 1040 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 1125 1128 1125 1128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 1299 1300 1299 1300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1402 1403 1402 1403 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1604 1605 1604 1605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1609 1613 1609 1613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1618 1619 1618 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1786 1802 1786 1802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 (c and d)</xref>
###xml 1893 1894 1893 1894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1898 1902 1898 1902 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1907 1908 1907 1908 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2018 2019 2018 2019 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2023 2024 2023 2024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2048 2049 2048 2049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2053 2054 2053 2054 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2108 2109 2108 2109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2147 2148 2147 2148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2152 2153 2152 2153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2158 2159 2158 2159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2218 2219 2218 2219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2223 2224 2223 2224 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2374 2375 2374 2375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2450 2451 2450 2451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2607 2608 2607 2608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
###xml 1419 1423 <span type="species:ncbi:10090">mice</span>
###xml 1487 1491 <span type="species:ncbi:10090">mice</span>
###xml 1936 1940 <span type="species:ncbi:10090">mice</span>
Our data indicate that CTLA-4 expression is important for the suppressive capacity of T reg cells. However, the impact of antibody-mediated CTLA-4 blockade of the T reg cell compartment was relatively modest in the in vitro suppressor assays (Fig. 2 d). Furthermore, our previous work had shown that depletion of T reg cells after tumor engraftment effected very different outcomes from those seen with prophylactic depletion before tumor challenge (Quezada et al., 2008). The lack of impact of T reg cell depletion on tumor growth as an isolated therapeutic strategy combined with the modest impact in vitro led us to question which cellular targets were important for the therapeutic antitumor activity of blocking antibodies in vivo. To address this question, we reconstituted immunodeficient RAG2-/- mice with cells from WT and HuTg donors (). After pan-T cell selection of cells derived from LN and spleen, purified populations of CD4+CD25+ T cells were mixed with the combined CD4+CD25- and CD8+ fractions (henceforth referred to as Teff) in four combinations to allow blockade of both compartments, T reg cells only, Teff only, or neither compartment (i.e., WT:WT, HuTg:WT, WT:HuTg, and HuTg:HuTg). We aimed for the T reg cell compartment to be 3-5% of the total cells or up to 10% of the CD4+ population, hence mirroring physiological levels (Fig. S5 a). After adoptive transfer of 1.8-2.0 x 107 total T cells, mice were left for 10 wk to allow equilibration. At this point, the mice were bled to assess equivalence before tumor challenge (Fig. S5 b). In all cases, the relative proportion of CD4+CD25highFoxp3+ was higher than in the infused mixture, and with a significantly higher number in those reconstituted with HuTg T reg cells. This finding mirrored those presented in Fig. 1 (c and d). T cell populations were stable between 6 and 10 wk after infusion (unpublished data). CD4+CD25highFoxp3+ cells in the reconstituted mice could derive from several sources, including expansion of the transferred CD4+CD25+ T cells or from the CD4+CD25- T cells through either peripheral conversion of FoxP3- cells or up-regulation of CD25 on CD4+CD25-FoxP3+ T cells. To confirm that the majority derived from the CD4+CD25+ T cell inoculum, we used a congenic marker to trace the transferred populations (Fig. S5 c). At 6 and 10 wk after transfer, the majority of the FoxP3+ T reg cell compartment in blood, LNs, and spleen was derived from the CD25+ inoculum. A median of 88.4% (range 80.2-92.0%) of circulating T reg cells were derived from this population, and similar numbers were derived from the CD25+ inoculum in both LNs and spleens (median 88.6 and 92.3%, respectively).
###end p 25
###begin p 26
###xml 199 200 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 228 236 224 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 a</xref>
###xml 263 283 259 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Quezada et al., 2006</xref>
###xml 454 462 450 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 b</xref>
###xml 609 629 605 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Quezada et al., 2008</xref>
###xml 736 742 732 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 779 782 775 778 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 901 916 897 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, b and c</xref>
###xml 1384 1399 1380 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, b and c</xref>
###xml 1500 1503 1496 1499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 592 607 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1340 1344 <span type="species:ncbi:10090">mice</span>
###xml 1414 1418 <span type="species:ncbi:10090">mice</span>
After B16/BL6 tumor challenge, all mice received combination therapy with aMuCTLA-4 (clone 9H10, 100 microg every 3 d from day 3) and an irradiated GM-CSF-secreting B16/BL6 cellular vaccine (Gvax, 106 cells on days 3, 6, and 9; Fig. 4 a) as previously described (Quezada et al., 2006). Tumor growth in mice in which CTLA-4 blockade affected only the T reg cell compartment did not differ significantly from those in which it targeted neither population (Fig. 4 b). This is consistent with our previous experience of therapeutic T reg cell depletion with either anti-CD25 mAbs or in Foxp3-DTR transgenic mice (Quezada et al., 2008) and with the minimal impact that CTLA-4 blockade had on T reg cell function in the in vitro experiments (Fig. 2). Unicompartmental blockade of the Teff cells resulted in a significant delay in tumor growth and improved rejection rates and long-term tumor-free survival (Fig. 4, b and c). Combined survival from three experiments was 12/30 (40%; P = 0.001 compared with unicompartmental blockade of T reg cells). Blockade in this instance would also have included that of induced T reg cells, but the additional blockade of the entire T reg cell compartment markedly enhanced antitumor activity. Thus, bicompartmental blockade resulted in synergy of antitumor activity, with tumor rejection in the majority of mice and much delayed growth in the others (Fig. 4, b and c). 22/30 (73%) mice were long-term survivors (P = 0.0017 compared with unicompartmental blockade of Teff).
###end p 26
###begin p 27
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTLA-4 blockade of effector and regulatory compartments synergizes to produce maximal antitumor activity.</bold>
###xml 232 233 232 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 297 298 297 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 470 473 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 503 506 503 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 539 542 539 542 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 583 586 583 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 610 611 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 801 802 801 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 442 446 <span type="species:ncbi:10090">mice</span>
###xml 747 751 <span type="species:ncbi:10090">Mice</span>
CTLA-4 blockade of effector and regulatory compartments synergizes to produce maximal antitumor activity. (a) Experimental design. RAG2-deficient mice were reconstituted with four combinations of WT and HuTg T reg and non-T reg (CD4+ and CD8+) cells. 10 wk later, they were challenged with 20 x 103 B16/BL6 melanoma cells intradermally. From day 3, they received combination immunotherapy with Gvax and aMuCTLA-4. (b) Tumor growth curves for mice reconstituted with WT Teff and T reg cells (red), HuTg Teff and WT T reg cells (green), WT Teff and HuTg T reg cells (black), and HuTg Teff and T reg cells (blue; n = 10 per group). Error bars indicate SEM. Data represent three independent experiments. (c) Survival curves with color coding as in b. Mice were euthanized when tumor volume exceeded 350 mm3. Pooled results from three independent experiments are shown.
###end p 27
###begin p 28
###xml 798 819 798 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Piconese et al., 2008</xref>
###xml 1218 1239 1218 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Sutmuller et al. 2001</xref>
###xml 1241 1261 1241 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Quezada et al., 2008</xref>
These data are significant for several reasons, highlighting the differences between genetic ablation of a molecule and antibody-mediated blockade. They demonstrate the absolute requirement for blockade on the effector compartment for the initiation of antitumor activity by anti-CTLA-4 in a therapeutic setting and also confirm the importance of CTLA-4 for optimal T reg cell function. Furthermore, they demonstrate the apparent synergy of the effects of blockade on effector and regulatory cells, revealing that only concomitant blockade of both compartments culminates in maximal antitumor activity. This duality of immunostimulatory function is perhaps unique among currently available clinical therapeutics, although TNF receptor agonists may also influence the function of both compartments (Piconese et al., 2008). Finally, they demonstrate that although the expression of CTLA-4 may be critical for suppressive function, outcomes after antibody-mediated blockade may be more subtle. This has great significance for the development of combinatorial immunotherapies and helps to explain the enhancement of antitumor activity obtained by approaches combining CTLA-4 blockade and therapeutic T reg cell depletion (Sutmuller et al. 2001; Quezada et al., 2008). The maintenance of significant suppressor function, despite antibody-mediated blockade during the in vitro assays, is consistent with T reg cells being able to use multiple suppressive mechanisms. The relative importance of each is likely to vary according to the model under study, leading to apparent redundancy after antibody-mediated blockade in some settings, but not others, and helping to explain the seemingly contradictory results of earlier studies.
###end p 28
###begin title 29
MATERIALS AND METHODS
###end title 29
###begin title 30

###end title 30
###begin title 31
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 31
###begin p 32
###xml 13 16 13 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 123 144 123 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Chambers et al., 1997</xref>
###xml 303 306 303 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 307 311 <span type="species:ncbi:10090">mice</span>
C57BL/6, RAG2-/-, and B6.SJL mice (6-8 wk old) were purchased from Taconic. CTLA-4-/- mice have been previously described (Chambers et al., 1997). HuTg mice were generated as documented in the text and in Fig. S1. In individual experiments, mice were age matched and used at 6-8 wk of age, except CTLA-4-/- mice which were 7-10 d of age. All animal experiments were approved by the Memorial Sloan-Kettering Cancer Center Institutional Animal Care and Use Committee.
###end p 32
###begin title 33
Antibodies.
###end title 33
###begin p 34
###xml 326 331 <span type="species:ncbi:9606">human</span>
###xml 364 369 <span type="species:ncbi:10090">mouse</span>
Anti-CTLA-4 (clone 9H10; BioExpress) was given i.p. for all in vivo studies. Anti-Ki67 FITC and aMuCTLA-4 PE (clone UC10-4F10-11; BD) were used according to manufacturer's instructions, whereas all other antibodies used for flow cytometry were purchased from eBioscience. For species-specific intracellular labeling, two anti-human (eBio20A and 14D3) and two anti-mouse (UC10-4F10-11 and 9H10) anti-CTLA-4 clones were used in independent experiments.
###end p 34
###begin title 35
In vitro suppression assays.
###end title 35
###begin p 36
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 202 203 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 207 208 207 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 387 388 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 392 393 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 566 588 558 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Takahashi et al., 2000</xref>
###xml 652 653 638 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 757 758 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 425 430 <span type="species:ncbi:10090">mouse</span>
###xml 989 994 <span type="species:ncbi:9606">human</span>
CD4+CD25+ and CD4+CD25- T cells were purified from LNs with magnetic beads (Miltenyi Biotec) according to the manufacturer's instructions (>95% purity). To test in vitro suppressive activity, 50,000 CD4+CD25- T cells were plated in round-bottom 96-well plates in the presence of 150,000 T cell-depleted irradiated splenocytes, 10 microg/ml purified anti-CD3 and increasing amounts of CD4+CD25+ T reg cells. Anti-MuCTLA-4 (or mouse IgG control) was added at a final concentration of 50 microg/ml, which has been described to have maximum effect in in vitro cultures (Takahashi et al., 2000). Cells were incubated at 37degreesC for 72 h and pulsed with [3H]thymidine in the last 8 h of culture, at the end of which the plates were harvested and analyzed for [3H]thymidine incorporation. Groups were analyzed in quintuplicate, and experiments were repeated at least three times. For experiments in which aHuCTLA-4 was used, the mAb was also added at a final concentration of 50 microg/ml and human IgG was used as the control.
###end p 36
###begin title 37
Cell lines.
###end title 37
###begin p 38
###xml 259 279 259 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Quezada et al., 2006</xref>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
The highly tumorigenic and poorly immunogenic melanoma cell line B16/BL6 was used for tumor challenge. B16/BL6-expressing GM-CSF, referred to in this paper as Gvax, was used for treatment of tumor-bearing mice. Both cell lines have been previously described (Quezada et al., 2006).
###end p 38
###begin title 39
Bone marrow chimeras.
###end title 39
###begin p 40
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 112 115 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 121 142 121 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Bachmann et al., 1999</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">2001</xref>
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 241 244 241 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 361 362 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 572 573 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 577 578 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 677 678 677 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 684 687 684 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 689 692 689 692 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
These were generated as previously described using bone marrow from the femurs of CD45.1+B6.SJL and CD45.2+CTLA4-/- mice Bachmann et al., 1999, 2001). Cells were mixed 50:50 and infused at a dose of 107 mononuclear cells per animal into RAG2-/- recipients 6 h after irradiation (300 cGy). 10-12 wk later, mice were bled to confirm mixed chimerism (40-60% CD45.1+). LNs were harvested, single cell suspensions prepared, and T cells selected using a pan-T cell purification kit (Miltenyi Biotech; negative selection). Anti-CD45.1 biotin was then added immediately before CD4+CD25+ T cell selection using a T reg cell selection kit (Miltenyi Biotech), allowing isolation of CD45.1-CTLA-4-/- Teff and T reg cells (Fig. S4).
###end p 40
###begin title 41
Tumor challenge and treatments.
###end title 41
###begin p 42
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 70 73 70 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 292 300 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 a</xref>
###xml 305 306 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">Mice</span>
RAG2-/- were injected via the tail vein with mixtures of WT and HuTg Teff and T reg cells as outlined in the text and in Fig. S5. 10 wk later, mice were challenged in the flank intradermally at day 0 with 20,000 B16/BL6 melanoma cell, and then treated with Gvax and aMuCTLA-4 (as detailed in Fig. 4 a). 106 irradiated (15O Gy) Gvax cells were injected intradermally (100 microl) in the contralateral flank on days 3, 6, and 9, while at the same time points, 100 microg of aMuCTLA-4 was injected i.p. in 200 microl PBS. Mice were monitored every 2-3 d for tumor growth.
###end p 42
###begin title 43
Statistical analyses.
###end title 43
###begin p 44
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Data were analyzed using Prism 4.0 (GraphPad Software, Inc.). Experiments were repeated two to three times as indicated. Statistical significance was determined by a Student's t test (between two groups or conditions) or analysis of variance with a post-hoc test (three or more groups or conditions). Data for tumor survival were analyzed according to the Kaplan-Meier method. The log-rank test was used to compare survival curves for different subgroups on univariate analyses. P-values <0.05 were considered statistically significant.
###end p 44
###begin title 45
Online supplemental material.
###end title 45
###begin p 46
###xml 376 379 376 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 471 474 471 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the scaled map of the 17-kb genomic DNA used for the generation of HuTg mice. Fig. S2 shows the regulation of cell surface and intracellular CTLA-4 expression in WT and HuTg mice in response to stimulation with anti-CD3. Fig. S3 shows in vitro suppressor assays using aHuCTLA-4 rather than aMuCTLA-4. Fig. S4 illustrates the approach used for isolation of CTLA-4-/- T reg cells from mixed bone marrow chimeras. Fig. S5 illustrates the reconstitution of RAG2-/- mice and subsequent assessment of peripheral blood, LN, and splenic phenotyping before tumor challenge. Online supplemental material is available at .
###end p 46
###begin title 47
Supplementary Material
###end title 47
###begin title 48
[Supplemental Material]
###end title 48
###begin p 49
We would like to dedicate this work to the memory of Dr Cynthia Chambers.
###end p 49
###begin p 50
###xml 135 139 <span type="species:ncbi:10090">mice</span>
We would like to acknowledge Mark Karlok, Jose Mendoza, and Chris Petromilli for their assistance in the generation of the HuTg CTLA-4 mice and Anne Trumble and Jocelyn Lu for technical assistance with some of the experiments.
###end p 50
###begin p 51
K.S. Peggs is currently an investigator at the Department of Haematology, University College London Cancer Institute, University College London, UK, and receives funding from the Leukaemia Research Fund, UK. S.A. Quezada is a Research Fellow funded by the Irvington Institute Fellowship Program of the Cancer Research Institute USA and a junior member of the Millennium Nucleus on Immunology and Immunotherapy, Pontificia Universidad Catolica de Chile. J.P. Allison is an investigator of the Howard Hughes Medical Institute and holds the David H. Koch Chair in Immunological Studies at the Memorial Sloan-Kettering Cancer Center. This work was also supported by The Experimental Therapeutics Center of Memorial Sloan-Kettering Cancer Center funded by William H. Goodwin and Alice Goodwin.
###end p 51
###begin p 52
Anti-CTLA-4 is currently in clinical development by Medarex and Bristol-Meyers Squibb. A.J. Korman is an employee of Medarex. J.P. Allison is a consultant for Medarex and Bristol-Meyers Squibb, and is an inventor of intellectual property that has been licensed to Medarex and Bristol-Myers Squibb by the University of California, Berkeley. The other authors have no other conflicting financial interests.
###end p 52
###begin article-title 53
Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
###end article-title 53
###begin article-title 54
Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: a paradigm reconsidered.
###end article-title 54
###begin article-title 55
ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells.
###end article-title 55
###begin article-title 56
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
###end article-title 56
###begin article-title 57
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
###end article-title 57
###begin article-title 58
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Thymocyte development is normal in CTLA-4-deficient mice.
###end article-title 58
###begin article-title 59
Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells.
###end article-title 59
###begin article-title 60
Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses.
###end article-title 60
###begin article-title 61
Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.
###end article-title 61
###begin article-title 62
Modulation of tryptophan catabolism by regulatory T cells.
###end article-title 62
###begin article-title 63
CTLA-4 regulates induction of anergy in vivo.
###end article-title 63
###begin article-title 64
CTLA-4 regulates cell cycle progression during a primary immune response.
###end article-title 64
###begin article-title 65
###xml 150 158 <span type="species:ncbi:9606">patients</span>
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
###end article-title 65
###begin article-title 66
Enhancement of antitumor immunity by CTLA-4 blockade.
###end article-title 66
###begin article-title 67
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
###end article-title 67
###begin article-title 68
###xml 73 77 <span type="species:ncbi:10090">mice</span>
B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
###end article-title 68
###begin article-title 69
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
###end article-title 69
###begin article-title 70
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
###end article-title 70
###begin article-title 71
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
###end article-title 71
###begin article-title 72
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
###end article-title 72
###begin article-title 73
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
###end article-title 73
###begin article-title 74
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.
###end article-title 74
###begin article-title 75
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation.
###end article-title 75
###begin article-title 76
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.
###end article-title 76
###begin article-title 77
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
###end article-title 77
###begin article-title 78
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
###end article-title 78
###begin article-title 79
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
###end article-title 79
###begin article-title 80
###xml 45 46 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 49 50 49 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
###end article-title 80
###begin article-title 81
Molecular interactions mediating T cell antigen recognition.
###end article-title 81
###begin article-title 82
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
###end article-title 82
###begin article-title 83
An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells.
###end article-title 83
###begin article-title 84
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
###end article-title 84
###begin article-title 85
CTLA-4 control over Foxp3+ regulatory T cell function.
###end article-title 85
###begin p 86
###xml 235 238 235 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eff</sub>
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 209 214 <span type="species:ncbi:9606">human</span>
Abbreviations used: aHuCTLA-4, anti-human CTLA-4; aMuCTLA-4, anti-mouse CTLA-4; ANA, antinuclear antibody; CKO, conditional KO; CTLA-4, CTL-associated antigen 4; Gvax, GM-CSF-secreting cellular vaccine; HuTg, human CTLA-4 transgenic; Teff, effector T cell; TKO, triple KO; T reg cell, regulatory T cell.
###end p 86

